Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30030516 | 0.81 | ACACB (0.44) | MTNR1AMTNR1B | |
| SCHEMBL29142419 | 0.81 | ACACB (0.44) | MTNR1AMTNR1B | |
| SCHEMBL10841119 | 0.69 | KDM4C (0.36) | — | |
| SCHEMBL30031339 | 0.68 | ACACB (0.43) | — | |
| SCHEMBL29142430 | 0.68 | ACACB (0.43) | — | |
| SCHEMBL30031586 | 0.66 | ACACB (0.44) | MTNR1AMTNR1B | |
| SCHEMBL29142417 | 0.66 | ACACB (0.44) | MTNR1AMTNR1B | |
| SCHEMBL12970659 | 0.62 | GRIN2B (0.40) | MTNR1AMTNR1B | |
| SCHEMBL20509893 | 0.60 | HTR2A (0.34) | HTR2C | |
| SCHEMBL17222061 | 0.60 | HTR2A (0.36) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CYP19A1 877/4885MTNR1A 320/4885MTNR1B 206/4885 |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CYP19A1 877/4885MTNR1A 320/4885MTNR1B 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.